Rofo 2005; 177(7): 962-967
DOI: 10.1055/s-2005-858268
Mamma

© Georg Thieme Verlag KG Stuttgart · New York

Teilbrustbestrahlung beim Mammakarzinom mit günstigen prognostischen Faktoren: 3-Jahres-Ergebnisse der deutsch-österreichischen Phase II-Studie

Partial Breast Irradiation for Early Breast Cancer: 3-Year Results of the German-Austrian Phase II-TrialO. J. Ott1 , R. Pötter2 , G. Hildebrandt3 , J. Hammer4 , M. Lotter1 , M. W. Beckmann5 , R. Sauer1 , V. Strnad1
  • 1Strahlenklinik, Universitätsklinikum Erlangen, Deutschland
  • 2Universitätsklinik für Strahlentherapie und Strahlenbiologie, AKH Wien, Österreich
  • 3Strahlenklinik, Universitätsklinikum Leipzig, Deutschland
  • 4Abteilung für Strahlentherapie, KH Barmherzige Schwestern Linz, Österreich
  • 5Frauenklinik, Universitätsklinikum Erlangen, Deutschland
Further Information

Publication History

Publication Date:
22 June 2005 (online)

Zusammenfassung

Ziel: Evaluierung von perioperativer Morbidität, Akut- und Spättoxizität sowie des kosmetischen Ergebnisses nach alleiniger interstitieller PDR- oder HDR-Brachytherapie des Tumorbetts nach brusterhaltender Operation. Material und Methoden: Zwischen November 2000 und November 2004 erhielten 240 Frauen nach brusterhaltender Operation wegen Mammafrühkarzinom eine alleinige PDR- oder HDR-Brachytherapie des Tumorbetts (Teilbrustbestrahlung). Wir präsentieren Ergebnisse der ersten 51 Patientinnen bezüglich Morbidität, Toxizität und Kosmetik. Die minimale bzw. mediane Nachbeobachtungszeit betrug 30 bzw. 36 Monate. Ergebnisse: Perioperative Morbidität: bakterielle Infektion des Implantats: 2 % (1/51); Akuttoxizität: Radiodermatitis Grad 1: 4 % (2/51); Spättoxizität: Brustschmerz Grad 1: 8 % (4/51), Grad 2: 2 % (1/51); Dyspigmentation Grad 1: 8 % (4/51); Fibrosierung Grad 1: 4 % (2/51), Grad 2: 8 % (4/51); Teleangiektasien Grad 1: 10 % (5/51), Grad 2: 4 % (2/51); kosmetisches Ergebnis: sehr gut und gut bei 94 % (48/51) der Patientinnen. Schlussfolgerung: Die Analyse zeigt, dass die interstitielle PDR-/HDR-Multikatheter-Brachytherapie des Tumorbetts (Teilbrustbestrahlung) allein nach brusterhaltender Operation mit niedriger perioperativer Komplikationsrate durchführbar, die Akuttoxizität niedrig und die Spättoxizität bei einer medianen Nachbeobachtungszeit von 36 Monaten mild war. Das kosmetische Ergebnis wurde bislang nicht signifikant beeinflusst.

Abstract

Purpose: To evaluate perioperative morbidity, toxicity and cosmetic outcome in patients treated with interstitial brachytherapy to the tumor bed as the sole radiation modality after breast conserving surgery. Materials and Methods: From 11/2000 to 11/2004, 240 women with early stage breast cancer participated in a protocol of tumor bed irradiation alone using pulsed dose rate (PDR) or high dose rate (HDR) interstitial multi-catheter implants (partial breast irradiation). Perioperative morbidity, acute and late toxicity as well as cosmetic outcome were assessed. Of the first 51 patients treated in this multicenter trial, we present interim findings after a median follow-up of 36 months. Results: Perioperative Morbidity: Bacterial infection of the implant: 2 % (1/51). Acute toxicity: radiodermatitis Grade 1: 4 % (2/51). Late toxicity: breast pain Grade 1: 8 % (4/51), Grade 2: 2 % (1/51); dyspigmentation Grade 1: 8 % (4/51); fibrosis Grade 1: 4 % (2/51), Grade 2: 8 % (4/51); telangiectasia Grade 1: 10 % (5/51), Grade 2: 4 % (2/51). Cosmetic results: Excellent and good in 94 % (48/51) of the patients. Conclusion: This analysis indicates that accelerated partial breast irradiation with 192-iridium interstitial multicatheter PDR-/HDR-implants (partial breast irradiation) is feasible with low perioperative morbidity, low acute and mild late toxicity at a median follow-up of 36 months. The cosmetic result is not significantly affected.

Literatur

  • 1 Van de Steene J, Vinh-Hung V, Cutuli B. et al . Adjuvant radiotherapy for breast cancer: effects of longer follow-up.  Radiother Oncol. 2004;  72 35-43
  • 2 Early Breast Cancer Trialists’ Collaborative Group (ed) . Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials.  Lancet. 2000;  355 1757-1770
  • 3 Ott O J, Pötter R, Hammer J. et al . Accelerated partial breast irradiation with Iridium-192 multicatheter PDR/HDR brachytherapy: preliminary results of the German-Austrian multicenter trial.  Strahlenther Onkol. 2004;  180 642-649
  • 4 Strnad V, Ott O, Pötter R. et al . Interstitial brachytherapy alone after breast conserving surgery: interim results of a German-Austrian multicenter phase II trial.  Brachytherapy. 2004;  3 115-119
  • 5 Keisch M, Vicini F, Kuske R R. et al . Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy.  Int J Radiat Oncol Biol Phys. 2003;  55 289-293
  • 6 Vicini F A, Remouchamps V, Wallace M. et al . Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy.  Int J Radiat Oncol Biol Phys. 2003;  57 1247-1253
  • 7 Vaidya J S, Tobias J S, Baum M. et al . Intraoperative radiotherapy for breast cancer.  Lancet Oncol. 2004;  5 165-173
  • 8 Orecchia R, Ciocca M, Lazzari R. et al . Intraoperative radiation therapy with electrons (ELIOT) in early-stage breast cancer.  Breast. 2003;  12 483-490
  • 9 Polgar C, Major T, Fodor J. et al . High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast-conserving surgery: seven-year results of a comparative study.  Int J Radiat Oncol Biol Phys. 2004;  60 1173-1181
  • 10 Benitez P R, Chen P Y, Vicini F A. et al . Partial breast irradiation in breast conserving therapy by way of intersitial brachytherapy.  Am J Surg. 2004;  188 355-364
  • 11 Arthur D W, Koo D, Zwicker R D. et al . Partial breast brachytherapy after lumpectomy: low-dose-rate and high-dose-rate experience.  Int J Radiat Oncol Biol Phys. 2003;  56 681-689
  • 12 Pierquin B, Dutreix A, Paine C H. et al . The Paris system in interstitial radiation therapy.  Acta Radiol Oncol Radiat Phys Biol. 1978;  17 33-48
  • 13 Fisher B, Anderson S, Redmond C K. et al . Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.  N Engl J Med. 1995;  333 1456-1461
  • 14 Veronesi U, Salvadori B, Luini A. et al . Breast conservation is a safe method in patients with small cancer of the breast: long-term results of three randomised trials of 1973 patients.  Eur J Cancer. 1995;  31 1574-1581
  • 15 Holli K, Saaristo R, Isola J. et al . Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study.  Br J Cancer. 2001;  84 164-169
  • 16 Liljegren G, Holmberg L, Bergh J. et al . 10-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial.  J Clin Oncol. 1999;  17 2326-2333
  • 17 Baglan K L, Martinez A A, Frazier R C. et al . The use of high-dose-rate brachytherapy alone after lumpectomy in patients with early-stage breast cancer treated with breast-conserving therapy.  Int J Radiat Oncol Biol Phys. 2001;  50 1003-1011
  • 18 King T A, Bolton J S, Kuske R R. et al . Long-term results of wide-field brachytherapy as the sole method of radiation therapy after segmental mastectomy for T(is,1,2) breast cancer.  Am J Surg. 2000;  180 299-304
  • 19 Krishnan L, Jewell W R, Tawfik O W. et al . Breast conservation therapy with tumor bed irradiation alone in a selected group of patients with stage I breast cancer.  Breast J. 2001;  7 91-96
  • 20 Kuske R R, Winter K, Arthur D. et al . A phase I/II trial of brachytherapy alone following lumpectomy for select breast cancer: toxicity analysis of Radiation Therapy Oncology Group 95 - 17.  Int J Radiat Oncol Biol Phys. 2002;  54 (Suppl) 87
  • 21 Lawenda B D, Taghian A G, Kachnic L A. et al . Dose-volume analysis of radiotherapy for T1N0 invasive breast cancer treated by local excision and partial breast irradiation by low-dose-rate interstitial implant.  Int J Radiat Oncol Biol Phys. 2003;  56 671-680
  • 22 Vicini F, Kini V R, Chen P. et al . Irradiation of the tumor bed alone after lumpectomy in selected patients with early-stage breast cancer treated with breast conserving therapy.  J Surg Oncol. 1999;  70 33-40
  • 23 Wazer D E, Berle L, Graham R. et al . Preliminary results of a phase I/II study of HDR brachytherapy alone for T1/T2 breast cancer.  Int J Radiat Oncol Biol Phys. 2002;  53 889-897
  • 24 Perera F, Engel F, Holliday R. et al . Local resection and brachytherapy confined to the lumpectomy site for early breast cancer: a pilot study.  J Surg Oncol. 1997;  65 263-268
  • 25 Polgar C, Sulyok Z, Fodor J. et al . Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: five-year results of a phase I-II study and initial findings of a randomized phase III trial.  J Surg Oncol. 2002;  80 121-128
  • 26 Vicini F A, Kestin L, Chen P. et al . Limited-field radiation therapy in the management of early-stage breast cancer.  J Natl Cancer Inst. 2003;  95 1205-1210

Dr. Oliver J. Ott

Universitätsklinikum Erlangen, Strahlenklinik

Universitätsstrasse 27

D-91054 Erlangen

Phone: ++ 49/91 31/8 53 29 35

Fax: ++ 49/91 31/8 53 93 35

Email: oliver.ott@strahlen.imed.uni-erlangen.de

    >